|
 |
|
|
CURRENT PUBLICATIONS
LABORATORY RESEARCH
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting Alpha-Ketoglutarate to 2-Hydroxyglutarate
Researchers report that tumor 2-hydroxyglutarate is elevated in a high percentage of patients with cytogenetically normal acute myeloid leukemia. [Cancer Cell]
Induction of Cell Cycle Entry Eliminates Human Leukemia Stem Cells in a Mouse Model of Acute Myeloid Leukemia
Using a NOD/SCID/IL2r(gamma)null mouse model of human acute myeloid leukemia (AML), researchers show that the AML stem cells in the endosteal region are cell cycle quiescent and that these stem cells can be induced to enter the cell cycle by treatment with granulocyte colony-stimulating factor. [Nature Biotechnol]
Apoptosis Induced by JAK2 Inhibition is Mediated by Bim and Enhanced by the BH3 Mimetic ABT-737 in JAK2 Mutant Human Erythroid Cells
JAK2 inhibition-induced apoptosis correlated with up-regulation of the non-phosphorylated form of the BH3-only protein Bim in hematopoietic cell lines bearing JAK2 mutations. [Blood]
Deletion of Puma Protects Hematopoietic Stem Cells and Confers Long-Term Survival in Response to High-Dose Gamma-Irradiation
Researchers have examined the role of p53 up-regulated mediator of apoptosis (PUMA) in apoptosis of hematopoietic stem cells after radiation injury. [Blood]
Integrated Analysis of MicroRNA and mRNA Expression Profiles in Physiological Myelopoiesis: Role of hsa-mir-299-5p in CD34+ Progenitor Cells Commitment
Gain- and loss-of-function experiments revealed that hsa-miR-299-5p participates in the regulation of hematopoietic progenitor fate, modulating megakaryocytic-granulocytic versus erythroid-monocytic differentiation. [Cell Death Differ]
Standards, Regulations and Accreditation for Registries Involved in the Worldwide Exchange of Hematopoietic Stem Cell Donors and Products
The World Marrow Donor Association is working closely with other international organizations working in cellular therapy such as the Worldwide Network for Blood and Marrow Transplantation to develop and maintain global recommendations and requirements for a standardized practice. [
Bone Marrow Transplant]
Increased Levels of NOTCH1, NF-KappaB, and Other Interconnected Transcription Factors Characterize Primitive Sets of Hematopoietic Stem Cells
To further evaluate the molecular basis related to the more primitive characteristics of umbilical cord blood (UCB) and CD133+ hematopoietic stem cells, immunomagnetically purified human CD34+ and CD133+ cells from bone marrow and UCB were used on gene expression microarrays studies. [Stem Cells Dev]
CLINICAL RESEARCH
Phase I Study of KW-0761, a Defucosylated Humanized Anti-CCR4 Antibody, in Relapsed Patients With Adult T-Cell Leukemia-Lymphoma and Peripheral T-Cell Lymphoma
KW-0761, a defucosylated humanized anti-CC chemokine receptor 4 (CCR4) antibody, exerts a strong antibody-dependent cellular cytotoxic effect. This phase I study assessed the safety, pharmacokinetics, recommended phase II dose and efficacy of KW-0761 in patients with relapsed CCR4-positive adult T cell leukemia-lymphoma or peripheral T cell lymphoma. [J Clin Oncol]
Favorable Outcome in Patients with Acute Myeloid Leukemia with NPM1 Mutation Autografted After Conditioning with High Dose Continuous Infusion Idarubicin and Busulphan
This study suggests that BuI regimen (based on high dose continuous infusion idarubicin and busulphan) results in favorable clinical outcome in patients with isolated NPM1 mutation and could be investigated in a randomized study versus other regimes or repeated courses of high dose cytosine-arabinoside. [Biol Blood Marrow Transplant]
Prognostic Significance of Genetic Variants in the IL-23/Th17 Pathway for the Outcome of T Cell-Depleted Allogeneic Stem Cell Transplantation
Results suggest the potential usefulness of IL-23/Th17 genotyping in donor selection and patient evaluation. [Bone Marrow Transplant]
|
|
INDUSTRY NEWS
Thermo Fisher Said to Offer $6 Billion for Millipore
Thermo Fisher Scientific Inc., the world's largest maker of lab instruments, made an unsolicited takeover offer of about $6 billion for Millipore Corp., according to a person close to the situation. [BusinessWeek]
Food and Drug Adminstration Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia
Genentech, Inc. and Biogen Idec announced the U.S. Food and Drug Administration approved Rituxan® (rituximab) in combination with fludarabine and cyclophosphamide for people with previously untreated and previously treated CD20-positive chronic lymphocytic leukemia. [Genentech Press Release]
Hematide ™ Entered into the Phase III Clinical Program to Treat Anemia in Chronic Renal Failure Patients in Japan
Takeda Pharmaceutical Company Limited announced that the investigational compound, Hematide™, of which Takeda and Affymax Inc. contracted the global license agreement, for the treatment of anemia in chronic renal failure has entered into phase III clinical program in Japan. [Takeda Press Release]
Novartis Drug Tasigna® Receives Food and Drug Administration Priority Review For Newly Diagnosed Patients With Early-Stage Chronic Myeloid Leukemia
Novartis announced that Tasigna® (nilotinib) has been granted priority review by the U.S. Food and Drug Administration for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. [Novartis Press Release]
EntreMed Receives Orphan Drug Designation for ENMD-2076 in Leukemia
EntreMed, Inc. announced that the U.S. Food and Drug Administration has granted orphan drug designation for the Company's lead oncology drug candidate, ENMD-2076, for the treatment of acute myeloid leukemia. [EntreMed Press Release]
|
|
POLICY NEWS
Food and Drug Administration Announces New Safety Plan for Agents Used to Treat Chemotherapy-Related Anemia
The U.S. Food and Drug Administration approved a risk management program to inform healthcare providers and their patients about the risks of a class of drugs called Erythropoiesis-Stimulating Agents. [Food and Drug Administration, United States]
Centers for Disease Control and Prevention to Monitor Reactions and Errors Associated with Blood Transfusions
The Centers for Disease Control and Prevention has launched the first national surveillance system to monitor adverse events in patients who receive blood transfusions. [Centers for Disease Control and Prevention, United States]
Review Considerations for Applications and Awards under the New NIH Guidelines for Human Stem Cell Research (NOT-OD-10-056) [National Institutes of Health, United States]
Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows (Parent F31) (PA-10-108) [National Institutes of Health, United States]
Ruth L. Kirschstein National Research Service Awards (NRSA) for Individual Postdoctoral Fellows (Parent F32) (PA-10-110) [National Institutes of Health, United States]
Ruth L. Kirschstein National Research Service Awards (NRSA) for Individual Senior Fellows (Parent F33) (PA-10-111) [National Institutes of Health, United States]
National Heart, Lung, and Blood Institute (NHLBI) Will Provide Limited Supplemental Support to the NIGMS Medical Scientist Training Program (MSTP) in FY 2010 (NOT-HL-11-103)
[National Heart, Lung, and Blood Institute, United States]
A Centralized Protein Sequence and Function Resource (U41) (RFA-HG-10-004) [National Human Genome Research Institute, United States]
2010 Meeting Materials, Vaccines and Related Biological Products Advisory Committee
[Food and Drug Administration, United States]
Consultation: Proposed Standards for Hematopoietic Progenitor Cells Intended for Use in Hematopoietic Reconstitution [Medicines and Healthcare Products Regulatory Agency, Australia]
|
|
EVENTS
2010 Bone Marrow Transplant (BMT) Tandem Meetings
February 24-28, 2010
Orlando, United States
36th Annual Meeting of the European Group for Blood & Marrow Transplantation (EBMT)
March 21-24, 2010
Vienna, Austria
12th Biennial Canadian Blood and Marrow Transplant Group (CBMTG) Conference
April 7-10, 2010
Vancouver, Canada
American Association for Cancer Research (AACR) 101st Annual Meeting 2010
April 17-21, 2010
Washington, DC, United States
International Society for Stem Cell Research (ISSCR) 8th Annual Meeting
June 16-19, 2010
San Francisco, United States
XXXIst International Congress of the International Society of Blood Transfusion (ISBT) in joint cooperation with the 43rd Congress of the German Society for Transfusion Medicine and Immunohematology (DGTI)
June 26-July 1, 2010
Berlin, Germany
Society for Hematology and Stem Cells (ISEH) 2010 Meeting
September 15-18, 2010
Melbourne, Australia
American Association of Blood Banks (AABB) Annual Meeting 2010
October 9-12, 2010
Baltimore, United States
52nd American Society of Hematology (ASH) Annual Meeting and Exposition
December 4-7, 2010
Orlando, United States
Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.
JOB OPPORTUNITIES
Research & Development Technologist (STEMCELL Technologies)
Manufacturing Sciences Technologist - Cell Culture (STEMCELL Technologies)
Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization's career opportunities with Cell Therapy News.
Visit here to post your career opportunities.
Have we missed an important article or publication in Hematopoiesis News? Click here to submit!
|
|
|
|
|
|
|
|
 |
